GT Biopharma Inc. (GTBP), a clinical-stage immuno-oncology company, on Friday announced first quarter results and provided updates on its developing pipeline.
The company is advancing cancer therapeutics through its proprietary Tetra-specific killer engager natural killer (TriKE NK) cell engager platform to utilize the patient's NK immune cells to fight cancer.
Q1 2026:
The company recorded a net loss of $2.83 million, or $0.11 per share in Q1 2026, while in the same period of 2025 the net loss was $0.78 million, or $0.33 per share. Losses were incurred due to higher losses from operations, amounting to $2.8 million, and interest expenses of $0.06 million.
Research and development expenses (R&D) were $0.41 million, considerably lower than the $1.09 million reported in the previous year, due to reduced preclinical costs.
Cash and cash equivalents on March 31, 2026, amounted to $8.92 million.
Pipeline Highlights:
The company is advancing GTB-3650 TriKE in treating CD33-positive malignancies, including refractory acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS). Enrollment in the Phase 1 trial is ongoing, and the study will evaluate safety, pharmacodynamics, pharmacokinetics, in vivo expansion of natural killer cells, and clinical activity.
GTB-5550 TriKE is a nanobody targeting B7H3 positive solid tumors, administered through a subcutaneous injection. The Phase 1a trial will determine the maximum tolerated dose (MTD) and the Phase 1b trial will enroll patients with various tumor types, including castration-resistant prostate cancer, ovarian cancer, breast cancer, head and neck cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer, to determine safety, tolerability, and preliminary anti-tumor activity.
GTBP is currently trading at $0.40, down 7.92%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.